Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03731364 · ClinicalTrials.gov registry record · Phase 2

Study of CA-008 (Vocacapsaicin) in Total Knee Arthroplasty

A Phase 2 study, sponsored by Concentric Analgesics.

Completed
Registry status
Phase 2
Development phase
55
Enrollment target

NCT03731364 is a Phase 2 study that has completed, run by Concentric Analgesics. The registered enrollment target is 55 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03731364, a Phase 2 study, has completed, sponsored by Concentric Analgesics.

COMPLETED
Registry status
Phase 2
Development phase
55 participants
Enrollment target

Study Summary

This is a two-part, Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 (vocacapsaicin) vs. placebo injected/instilled during an elective TKA.

Interventions

  • DRUG Placebo
  • DRUG CA-008

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2018-10-29
Est. Completion 2019-05-31
Phase Phase 2

Sponsor

Concentric Analgesics

7 total trials

What the Registry Record Tells You About NCT03731364

The ClinicalTrials.gov registry entry for NCT03731364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concentric Analgesics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03731364 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03731364 about?

NCT03731364 is a clinical study titled "Study of CA-008 (Vocacapsaicin) in Total Knee Arthroplasty". This is a two-part, Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 (vocacapsaicin) vs. placebo injected/instilled during an elective TKA.

What is the current status of trial NCT03731364?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2018-10-29. Estimated completion is 2019-05-31.

What interventions are being tested in trial NCT03731364?

The interventions under investigation include: Placebo (DRUG), CA-008 (DRUG).

Who is sponsoring clinical trial NCT03731364?

This trial is sponsored by Concentric Analgesics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.